Xtant Medical Holdings, Inc. Announces Date of 2025 Annual Meeting of Stockholders

Strategic Insights -

Xtant Medical Holdings, Inc., a leading medical device company, has established November 7, 2025, as the date of its 2025 Annual Meeting of Stockholders. This change in date is subject to certain requirements and procedures outlined in the company's proxy statement, which is expected to be printed and mailed to stockholders on or about September 12, 2025.

The company's Board of Directors has set forth procedures for stockholders to present proposals for inclusion in the proxy materials relating to the 2025 Annual Meeting. Stockholders who wish to present proposals must submit them by August 18, 2025, and must satisfy the requirements of the proxy rules promulgated by the Securities and Exchange Commission (SEC). Additionally, stockholders who intend to solicit proxies in support of director nominees other than the company's nominees must comply with the "universal proxy rules" and provide written notice to the company by September 8, 2025.

Key Takeaways:

  • The 2025 Annual Meeting of Stockholders of Xtant Medical Holdings, Inc. has been scheduled for November 7, 2025.
  • The company's proxy statement, setting forth procedures for stockholder proposals and nominations, is expected to be printed and mailed to stockholders on or about September 12, 2025.
  • Stockholders who wish to present proposals must submit them in writing to the company's Corporate Secretary by August 18, 2025.
  • Stockholders who intend to solicit proxies in support of director nominees other than the company's nominees must comply with the "universal proxy rules" and provide written notice to the company by September 8, 2025.
  • The company's Third Amended and Restated Bylaws provide for an advance notice procedure with regard to nominations of persons for election to the Board.

Statistics:

  • The date of the 2025 Annual Meeting of Stockholders is November 7, 2025.
  • The company's proxy statement is expected to be printed and mailed to stockholders on or about September 12, 2025.
  • Stockholders have until August 18, 2025, to submit proposals for inclusion in the proxy materials.
  • Stockholders who intend to solicit proxies in support of director nominees other than the company's nominees must comply with the "universal proxy rules" and provide written notice to the company by September 8, 2025.
  • The company's Third Amended and Restated Bylaws require stockholders who wish to present proposals to be given in writing to the Corporate Secretary and delivered to the company no later than August 18, 2025.

Sources:

  • Xtant Medical Holdings, Inc. (2025). Form 8-K (Current Report) (Aug 08, 2025).
  • Securities and Exchange Commission (2025). Rule 14a-8 under the Securities Exchange Act of 1934.
  • Securities and Exchange Commission (2025). Rule 14a-19 under the Securities Exchange Act of 1934.